NDA 020064 · Almatica
Macrobid
Nitrofurantoin, Nitrofurantoin, Macrocrystalline · Oral · Nitrofuran Antibacterial
Last checked: Nov 19, 2026Latest source record: Mar 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Dec 24, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
78
11 Phase 3, 18 recruiting
FAERS reports
5,883
4,020 serious, 335 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 24, 2026.
INDICATIONS AND USAGE Nitrofurantoin capsules (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus . Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (monohydrate/macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (monohydrate/macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (monohydrate/macrocrystals) are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES . ) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (monohydrate/macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (monohydrate/macrocrystals) lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of...
Mechanism: Mechanism of Action The mechanism of the antimicrobial action of nitrofurantoin is unusual among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates which inactivate or alter bacterial ribosomal proteins and other macromolecules. As a result of such inactivations, the vital biochemical processes of protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. Nitrofurantoin is bactericidal in urine at therapeutic doses. The broad-based nature of this mode of action may explain the lack of acquired...
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 24, 1991 Original approval · Type 3 - New Dosage Form
1 products under this application
- MACROBID · NITROFURANTOIN 75MG; NITROFURANTOIN, MACROCRYSTALLINE 25MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Nitrofurantoin" as an intervention, any sponsor and status, largest first.
- Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04187144 · 1,606 participants · Start Apr 23, 2020 · Primary completion Dec 1, 2022
Drug: Gepotidacin; Placebo matching nitrofurantoin and 2 more · For: Urinary Tract Infections
Sites: Birmingham, Alabama; Homewood, Alabama; Huntsville, Alabama · 113 sites in all
- A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04020341 · 1,531 participants · Start Oct 17, 2019 · Primary completion Nov 30, 2022
Drug: Gepotidacin; Placebo matching nitrofurantoin and 2 more · For: Urinary Tract Infections
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 103 sites in all
- Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE CountriesPivotal-lookingRecruiting
NICHD Global Network for Women's and Children's HealthResearch network
NCT06723392 · 1,134 participants (planned) · Start Dec 8, 2025 · Primary completion Sep 2028
Drug: Oral nitrofurantoin monohydrate/macrocrystals · For: Preterm Birth; Small for Gestational Age (SGA); Stillbirth and 1 more
Sites: Dhaka, Bangladesh; Kinshasa, Democratic Republic of the Congo; Guatemala City, Guatemala · 7 sites in all
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.Pivotal-lookingCompleted
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaAcademic, hospital or other
NCT04959331 · 1,000 participants · Start Nov 2, 2021 · Primary completion Dec 14, 2024
Drug: Fosfomycin Trometamol Salt; Nitrofurantoin and 2 more · For: Urinary Tract Infections
Sites: Calatayud, Spain; Zaragoza, Spain; Calvià, Spain · 33 sites in all
- Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in WomenPivotal-lookingStatus unknown
University Hospital, GenevaAcademic, hospital or other
NCT01966653 · 600 participants (planned) · Start Oct 2013 · Primary completion May 2017
Drug: nitrofurantoin; fosfomycin · For: Urinary Tract Infections; Cystitis
Sites: Tel Aviv, Israel; Lodz, Poland; Geneva, Switzerland
- Antibiotic Prophylaxis for Clean Intermittent CatheterisationPivotal-lookingCompleted
Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
NCT02145338 · 404 participants · Start Sep 2013 · Primary completion Feb 22, 2017
Drug: Nitrofurantoin or Trimethoprim or Cefalexin · For: Urinary Tract Infections, Recurrent
Sites: Newcastle upon Tyne, United Kingdom
- Nitrofurantoin Macrocrystals 3 Days Versus 7 Days in the Treatment of Women With Uncomplicated CystitisPivotal-lookingWithdrawn
HaEmek Medical Center, IsraelAcademic, hospital or other
NCT00361998 · 400 participants · Start Sep 2006
Drug: NITROFURANTOIN MACROCRYSTALS · For: Cystitis
Sites: Haifa, Israel
- COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMENPivotal-lookingStatus unknown
Shalamar Institute of Health SciencesAcademic, hospital or other
NCT06518291 · 392 participants (planned) · Start Jan 2025 · Primary completion Jun 2025
Drug: Nitrofurantoin 100 MG; Fosfomycin · For: Urinary Tract Infections
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- urinary tract infection820
- headache623
- nausea590
- drug hypersensitivity552
- fatigue537
- pain505
- dyspnoea444
- drug ineffective438
- off label use398
- diarrhoea373
- dizziness370
- vomiting347
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 85 |
| 2005 | 83 |
| 2006 | 103 |
| 2007 | 80 |
| 2008 | 99 |
| 2009 | 126 |
| 2010 | 177 |
| 2011 | 249 |
| 2012 | 274 |
| 2013 | 227 |
| 2014 | 329 |
| 2015 | 385 |
| 2016 | 500 |
| 2017 | 406 |
| 2018 | 400 |
| 2019 | 432 |
| 2020 | 469 |
| 2021 | 294 |
| 2022 | 255 |
| 2023 | 249 |
| 2024 | 229 |
| 2025 | 261 |
| 2026 | 171 |
Recalls
3 FDA enforcement reports for this application.
Jul 24, 2019 · Class II · Terminated
Failed dissolution specifications
Jul 24, 2019 · Class II · Terminated
Failed dissolution specifications
Apr 21, 2015 · Class II · Terminated
Failed Dissolution Specification; 6 month time point
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Macrobid (Nitrofurantoin Monohyd/M-Cryst)
2024 spending
$75K
Beneficiaries
399
590 claims
Per beneficiary
$188
$5.65 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $79,074 |
| 2021 | $53,957 |
| 2022 | $57,114 |
| 2023 | $63,981 |
| 2024 | $74,940 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.
Wagenlehner F, Perry CR, Hooton TM, et al. · Lancet 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Nitrofurantoin disposition.
Hoener B, Patterson SE · Clin Pharmacol Ther 1981 · Clinical Trial, Randomized Controlled Trial
- Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.
Huttner A, Kowalczyk A, Turjeman A, et al. · JAMA 2018 · Comparative Study, Multicenter Study
- Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial.
Llor C, Monfà R, Garcia-Sangenís A, et al. · Lancet 2026 · Multicenter Study, Pragmatic Clinical Trial
- Fact versus Fiction: a Review of the Evidence behind Alcohol and Antibiotic Interactions.
Mergenhagen KA, Wattengel BA, Skelly MK, et al. · Antimicrob Agents Chemother 2020 · Research Support, U.S. Gov't, Non-P.H.S., Systematic Review
- D-mannose for preventing and treating urinary tract infections.
Cooper TE, Teng C, Howell M, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.